Lead Plaintiff Deadline is Approaching - Act Now

Humacyte, Inc.® Shareholder Class Action

Cutshall v. Humacyte, Inc. et al.

Humacyte, Inc.®

NASDAQ: HUMA

Class Period : 05/10/2024 - 10/17/2024

Lead Plaintiff Motion Deadline: 1/17/2025

A class action lawsuit has been filed against Humacyte, Inc.®, alleging that the company made false and misleading statements regarding its business practices and regulatory compliance. Humacyte submitted a Biologics License Application (BLA) to the FDA for its Acellular Tissue Engineered Vessel (ATEV) for urgent arterial repairs. The FDA granted Priority Review, setting an approval decision date of August 10, 2024. However, the company's manufacturing facility in Durham, North Carolina, was later found to have serious compliance issues, delaying FDA approval and significantly impacting investor confidence. These allegations have left many shareholders questioning the company's transparency and business practices.  

Alleged Misstatements and Omissions  

The lawsuit claims Humacyte failed to disclose critical problems, including:  

  1. Non-compliance with good manufacturing practices at its Durham facility.  
  2. Quality assurance and microbial testing deficiencies.  
  3. A high risk of delayed FDA approval for ATEV.  
  4. Misleadingly positive statements about the company's operations and prospects.  

These omissions and misstatements painted an overly optimistic picture of Humacyte's position, deceiving investors about potential risks and challenges.  

Effects on Stock Prices  

Humacyte's stock price suffered two significant declines after revelations about its regulatory troubles:  

  • August 9, 2024: After announcing the FDA needed more time to review the BLA due to facility issues, the stock dropped 16.4%, closing at $6.62 per share on August 12.  
  • October 17, 2024: Following the FDA's release of Form 483 detailing violations like poor microbial testing and oversight, the stock plunged another 16.35%, closing at $4.86 per share.  

Investors who purchased shares during this period saw significant losses due to Humacyte's alleged lack of transparency about its manufacturing deficiencies.  

Legal Rights for Affected Shareholders  

Shareholders have legal rights when a company misrepresents material facts that result in financial harm. By joining this class action, you can pursue compensation for:  

  • Losses incurred due to misleading statements.  
  • Financial damages are tied to regulatory delays.  
  • The company's failure to disclose risks accurately.  

If you purchased Humacyte stock and suffered losses, you may qualify to participate in this class action. An experienced attorney can guide you through the process and help you fight for justice.  

Take Action Today  

Don't let your investment losses go unanswered. If you believe Humacyte's actions negatively impacted your financial interests, now is the time to act. You can seek compensation and hold the company accountable for its alleged misconduct by joining the class action.  

Here’s what you can do:  

  1. Collect records of your Humacyte stock purchases and sales.  
  2. Document financial losses tied to these transactions.  
  3. Contact a qualified class action attorney to discuss your case.  

The time to join the lawsuit may be limited, so take the first step today to protect your rights.

iStock-14

DiCello Levitt Fights to Protect Shareholder Rights  

At DiCello Levitt, we are dedicated to representing shareholders harmed by corporate misconduct. Our experienced legal team is committed to holding companies accountable when they mislead investors and cause financial losses. With a proven track record in securities litigation, we understand what it takes to build a strong case and fight for maximum compensation.  

If you've suffered losses due to Humacyte's alleged misstatements, we're here to help. Contact us today for a free, confidential case evaluation. Learn about your legal options and determine the potential value of your claim. Don't wait—let us advocate for your rights and help you seek the justice you deserve.

All victims affected by Humacyte, Inc.®'s alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

Find Out if You may be a Member
of the Class

Oops! We could not locate your form.

*Consent: If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form above. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit. By clicking the "SUBMIT" button, I consent to receive recurring auto dialed and/or text messages from Stock Fraud Claim, DiCello Levitt, and Tort Intake Professionals LLC or our partners in order to discuss my legal options and at the telephone number I provided. I also consent to the Stock Fraud Claim Privacy Policy and Terms of Use. I understand that I may receive a call even if my telephone number is listed on a Do Not Call list and that my consent is not a requirement of purchase. I understand that my telephone company may impose charges on me for these contacts and that I can revoke this consent at any time. For SMS campaigns: Text STOP to cancel and HELP for help. Msg & data rates may apply. Recurring msgs up to 27 msgs per month.

Humacyte, Inc.® Shareholder Class Action

Cutshall v. Humacyte, Inc. et al.

Humacyte, Inc.®

NASDAQ: HUMA

Class Period : 05/10/2024 - 10/17/2024

Lead Plaintiff Motion Deadline: 1/17/2025

A class action lawsuit has been filed against Humacyte, Inc.®, alleging that the company made false and misleading statements regarding its business practices and regulatory compliance. Humacyte submitted a Biologics License Application (BLA) to the FDA for its Acellular Tissue Engineered Vessel (ATEV) for urgent arterial repairs. The FDA granted Priority Review, setting an approval decision date of August 10, 2024. However, the company's manufacturing facility in Durham, North Carolina, was later found to have serious compliance issues, delaying FDA approval and significantly impacting investor confidence. These allegations have left many shareholders questioning the company's transparency and business practices.  

Alleged Misstatements and Omissions  

The lawsuit claims Humacyte failed to disclose critical problems, including:  

  1. Non-compliance with good manufacturing practices at its Durham facility.  
  2. Quality assurance and microbial testing deficiencies.  
  3. A high risk of delayed FDA approval for ATEV.  
  4. Misleadingly positive statements about the company's operations and prospects.  

These omissions and misstatements painted an overly optimistic picture of Humacyte's position, deceiving investors about potential risks and challenges.  

Effects on Stock Prices  

Humacyte's stock price suffered two significant declines after revelations about its regulatory troubles:  

  • August 9, 2024: After announcing the FDA needed more time to review the BLA due to facility issues, the stock dropped 16.4%, closing at $6.62 per share on August 12.  
  • October 17, 2024: Following the FDA's release of Form 483 detailing violations like poor microbial testing and oversight, the stock plunged another 16.35%, closing at $4.86 per share.  

Investors who purchased shares during this period saw significant losses due to Humacyte's alleged lack of transparency about its manufacturing deficiencies.  

Legal Rights for Affected Shareholders  

Shareholders have legal rights when a company misrepresents material facts that result in financial harm. By joining this class action, you can pursue compensation for:  

  • Losses incurred due to misleading statements.  
  • Financial damages are tied to regulatory delays.  
  • The company's failure to disclose risks accurately.  

If you purchased Humacyte stock and suffered losses, you may qualify to participate in this class action. An experienced attorney can guide you through the process and help you fight for justice.  

Take Action Today  

Don't let your investment losses go unanswered. If you believe Humacyte's actions negatively impacted your financial interests, now is the time to act. You can seek compensation and hold the company accountable for its alleged misconduct by joining the class action.  

Here’s what you can do:  

  1. Collect records of your Humacyte stock purchases and sales.  
  2. Document financial losses tied to these transactions.  
  3. Contact a qualified class action attorney to discuss your case.  

The time to join the lawsuit may be limited, so take the first step today to protect your rights.

iStock-14

DiCello Levitt Fights to Protect Shareholder Rights  

At DiCello Levitt, we are dedicated to representing shareholders harmed by corporate misconduct. Our experienced legal team is committed to holding companies accountable when they mislead investors and cause financial losses. With a proven track record in securities litigation, we understand what it takes to build a strong case and fight for maximum compensation.  

If you've suffered losses due to Humacyte's alleged misstatements, we're here to help. Contact us today for a free, confidential case evaluation. Learn about your legal options and determine the potential value of your claim. Don't wait—let us advocate for your rights and help you seek the justice you deserve.

All victims affected by Humacyte, Inc.®'s alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

100% Free & Secure Case Evaluations

Answer a few basic questions to get started

We'll ask specific questions to understand the situation, damage risk, and other vital information to help determine the next steps.

Receive a confidential evaluation

A qualified legal team led by a Financial Products Litigation attorney will consider the facts of your case.

Humacyte, Inc.®'s Investors may have grounds to pursue legal action and financial recovery of damages.

This website offers general information only and is not legal or investment advice. This advertisement is not associated with any government agency.

www.stockfraudclaim.com is the property of Shield Legal LLC. 5170 Badura Ave Las Vegas, NV 89118

Participating law firm: DiCello Levitt LLP, 10 North Dearborn Street Sixth Floor Chicago, IL 60602. For additional terms, disclaimers, and conditions, please visit https://dicellolevitt.com/privacy-policy/

This website is not part of the Facebook website or Facebook, Inc., and it is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of Facebook, Inc.

ATTORNEY ADVERTISING. This Website does not provide investment, legal, or medical advice. Every case is evaluated on its facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. Stock Fraud Claim does not itself provide legal services. Cases will be referred to third-party attorneys and law firms.  Court costs and case expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement, or dramatization and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either expressed or implied. Anyone considering a lawyer should independently investigate the lawyer's credentials and ability, and not rely upon advertisements or self-proclaimed expertise. Only persons age 18 or older have permission to access our Service. Our Service does not address anyone under 13 ("Children").

NO ATTORNEY-CLIENT RELATIONSHIP. Use of this website, including sending or receiving information through it, does not establish an attorney-client relationship, nor is any non-passworded information considered privileged or confidential. No class has been certified.  Until a case is filed and a class is certified, you are not represented by counsel unless you retain one.  You may select counsel of your choice.  An attorney-client relationship with DiCello Levitt is established only by an express written agreement signed by DiCello Levitt to represent you.

Attorney Advertising.  Prior results do not guarantee a similar outcome.

Privacy Policy | Terms and Conditions | CCPA Privacy Notice | Do Not Sell My Info

©2024 Stock Fraud Claim. All Rights Reserved